Zacks Research downgraded shares of Lifeward (NASDAQ:LFWD – Free Report) from a hold rating to a strong sell rating in a research report released on Wednesday morning,Zacks.com reports.
LFWD has been the topic of several other reports. HC Wainwright upped their target price on Lifeward to $10.00 and gave the stock a “buy” rating in a research report on Thursday, March 19th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Lifeward in a research note on Tuesday, April 21st. One analyst has rated the stock with a Buy rating and two have given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Reduce” and a consensus target price of $10.00.
Get Our Latest Stock Analysis on LFWD
Lifeward Trading Down 1.5%
Lifeward (NASDAQ:LFWD – Get Free Report) last announced its quarterly earnings data on Friday, May 15th. The company reported ($6.70) earnings per share for the quarter, missing the consensus estimate of ($1.18) by ($5.52). The firm had revenue of $3.92 million during the quarter, compared to analyst estimates of $5.78 million. Lifeward had a negative net margin of 123.66% and a negative return on equity of 243.14%. On average, equities analysts forecast that Lifeward will post -4.27 EPS for the current fiscal year.
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in the stock. HRT Financial LP increased its holdings in shares of Lifeward by 149.7% during the 4th quarter. HRT Financial LP now owns 49,081 shares of the company’s stock valued at $28,000 after acquiring an additional 29,423 shares during the last quarter. Jane Street Group LLC increased its holdings in shares of Lifeward by 77.3% during the 4th quarter. Jane Street Group LLC now owns 68,631 shares of the company’s stock valued at $40,000 after acquiring an additional 29,927 shares during the last quarter. Virtu Financial LLC grew its holdings in Lifeward by 158.0% in the 4th quarter. Virtu Financial LLC now owns 60,474 shares of the company’s stock valued at $35,000 after buying an additional 37,037 shares during the last quarter. Finally, Citadel Advisors LLC grew its holdings in Lifeward by 1,271.8% in the 3rd quarter. Citadel Advisors LLC now owns 214,006 shares of the company’s stock valued at $152,000 after buying an additional 198,406 shares during the last quarter. Institutional investors and hedge funds own 26.76% of the company’s stock.
Trending Headlines about Lifeward
Here are the key news stories impacting Lifeward this week:
- Negative Sentiment: HC Wainwright cut Lifeward’s 2026 earnings outlook sharply, now expecting a much larger loss per share for FY2026 than previously forecast. Lifeward analyst estimates
- Negative Sentiment: The firm also reduced Q2 2026, Q3 2026, and Q4 2026 EPS estimates, suggesting weaker profitability in the near term. Lifeward analyst estimates
- Negative Sentiment: HC Wainwright lowered longer-term EPS projections for FY2027, FY2028, and FY2029 as well, indicating a slower path to earnings recovery. Lifeward analyst estimates
- Neutral Sentiment: Despite the lower estimates, HC Wainwright kept a Buy rating and a $10 price target on Lifeward, implying the firm still sees upside from current levels. Lifeward analyst estimates
- Positive Sentiment: HC Wainwright raised its FY2030 EPS estimate, suggesting the company could eventually return to stronger profitability over the long term. Lifeward analyst estimates
About Lifeward
ReWalk Robotics Ltd., a medical device company, designs, develops, and commercializes technologies that enable mobility and wellness in rehabilitation and daily life for individuals with physical and neurological conditions in the United States, Europe, the Asia-Pacific, and internationally. It offers ReWalk personal exoskeleton and rehabilitation exoskeleton devices; ReStore, a soft exo-suit intended for use in the rehabilitation of individuals with lower limb disability due to stroke; AlterG Anti-Gravity System for use in physical and neurological rehabilitation and athletic training; MyoCycle devices; and ReBoot, a personal soft exo-suit for home and community use by individuals post-stroke.
Featured Stories
- Five stocks we like better than Lifeward
- The Great AI Server Rotation Puts Hewlett Packard Enterprise and Super Micro Computer in Focus
- Generac’s AI Power Pivot Raises a Bigger Question About Data Center Demand
- Medtronic Bottoms, Healthy Rebound Ahead
- GitLab’s Price Recovery Gains Traction—Time to Get On Board?
Receive News & Ratings for Lifeward Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lifeward and related companies with MarketBeat.com's FREE daily email newsletter.
-PUNDIX.png){kind=small}
